Mechanisms of Action of Phytochemicals from Medicinal Herbs in the Treatment of Alzheimer’s Disease

Abstract

Alzheimer’s disease is a chronic neurodegenerative disorder characterized by progressive dementia and deterioration of cognitive function. Although several drugs currently used for the treatment of Alzheimer’s disease delay its onset and slow its progression, still there is no drug with profound disease-modifying effects. Studies aiming the treatment of this neurodegenerative disorder explore various disease mechanisms. Since antiquity, medicinal herbs have been used in traditional medicine. Recent studies suggest that the neurobiological effects of phytochemicals from medicinal herbs may contribute to clinical benefits in in vitro and in vivo models of Alzheimer’s disease. This review focuses on five phytochemicals, berberine, curcumin, ginsenoside Rg1, puerarin, and silibinin, which have been mostly investigated to treat the development and progression of this neurodegenerative disorder.

Abbreviations

AchE: acetylcholinesterase  
AD: Alzheimer’s disease  
Akt: protein kinase B  
Aβ: β-amyloid  
APP: amyloid precursor protein  
BACE: β-secretase or beta-site amyloid precursor protein cleaving enzyme  
Bax: Bcl-2-associated X protein  
Bcl-2: B-cell leukemia protein  
BDNF: brain-derived neurotrophic factor  
CAT: catalase  
Cox: cyclooxygenase  
CTF: C terminal fragment  
Cyt c: cytochrome c  

ELISA: enzyme-linked immunosorbent assay  
FDA: Food and Drug Administration  
γ-GCS: γ-glutamylcysteine  
GFAP: glial fibrillary acidic protein  
GRg1: ginsenoside Rg1  
GSH-Px: glutathione peroxidase  
GSK3β: glycogen synthase kinase  
Iba-1: ionized calcium binding adaptor molecule-1  
IL: interleukin  
i-Nos: inducible nitric oxide synthase  
JNK: c-Jun N-terminal kinase  
LDH: lactate dehydrogenase  
MAP-2: microtubule-associated protein  
MCP-1: monocyte chemoattractant protein-1  
MDA: malondialdehyde  
MWM task: Morris water maze task  
NF-κB: nuclear factor-κB  
NICE: National Institute for Health and Clinical Excellence  
NO: nitric oxide  
p-ERK1/2: extracellular signal-regulated kinase 1 and 2  
P38: phosphoinositide 3-kinase  
PS1: presenilin 1  
PTEN: phosphatase and tensin homolog  
RAWM: radial arm water maze  
RNS: reactive nitrogen species  
ROS: reactive oxygen species  
SYN: synaptophysin  
TEM: transmission electron microscopy  
ThT: thioflavin T  
(TNF)-α: tumor necrosis factor-α  
TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling
Introduction

AD, a progressive irreversible neurodegenerative disorder characterized by the loss of certain cognitive functions, behavioral disturbances, and daily living difficulties, is the most common form of dementia found among elderly individuals [1]. This disease currently affects 27 million people all over the world [2]. The prevalence rate for AD has become the third greatest threat to the elderly, only behind cardiovascular disease and cancer [3]. Although neither a consensus concerning the pathogenesis of AD nor a perfect therapy for its treatment is available, it is now well accepted that multiple factors, including apoptosis, oxidative stress, excitotoxicity, and the disturbance of energy metabolism homeostasis, contribute to the progression of AD [4]. Especially, the aggregation and accumulation of extracellular and intracellular Aβ play a critical role in the pathogenesis of AD and result in impaired synaptic plasticity and memory [5]. As a key rate-limiting enzyme, α-, β-, and γ-site amyloid precursor protein cleaving enzyme (α-, β-, and γ-secretase) initiates the formation of Aβ by producing the peptide from APP [6]. APP can be cleaved in two ways, with formation of non-toxic Aβ1-42 by α- and γ-secretases and the generation of toxic Aβ1-40 by β- and γ-secretases [7]. Therefore, inhibiting the activity of β-secretases is important for treating AD due to their role in the direct cleavage of the Aβ domain at the N-terminus in APP [8]. These changes are closely associated with tau phosphorylation and PI3K/Akt/GSK3β signaling pathway along with MAPK signaling. The Akt-mediated control of GSK3β activity is involved in tau hyperphosphorylation [9]. Aβ generation by the cleavage of APP triggers immune responses and activates microglial cells that engulf Aβ filaments, with secretion of various pro-inflammatory factors [9, 10]. In addition, neuron-related apoptosis and oxidative stress lead to neuronal damage [11].

Numerous in vitro and in vivo models have been used for studying AD. Various types of cells were stimulated with neurodegenerative exposures such as to subtypes of Aβ and acrolein. Aβ deposition causes synaptic plasticity and memory impairment and has been detected in AD patients at early stage [12]. Acrolein is not only a marker of lipid peroxidation but also an inducer of oxidative stress and an effector of tissue damage [13]. With growing evidence of the implication of acrolein in AD, the development of strategies to reduce its toxic effect is of great importance [12].

Cognitive impairments in animal models are analyzed with behavioral tests, such as MWM task and Y-maze, RAWM, novel object recognition as well as cued and contextual fear-conditioning tests, which are known to be sensitive to hippocampal-dependent learning and memory deficits. Specifically, TgCRND8 mice expressing human APP695 with the Swedish (K670N/M671L) and Indiana (V717F) mutations under regulatory control of the PrP gene promoter (heterozygous with respect to the transgene) on a C57BL/6 F3 background are used to breed the colony of experimental animals [14], while transgenic mouse overexpressing of APP/Aβ (Tg mAPP) is a well-used mouse model of AD [15, 16]. Despite great effort to discover a remedy for AD, no currently available drug can stop or cure this neurodegenerative disorder, and current treatments offer only small symptomatic benefits. The most commonly prescribed drugs are cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, and NMDA antagonists such as memantine. Though approved by the FDA, these drugs are not recommended by the NICE in England and Wales due to “limited and largely inconclusive” evidence concerning their efficacy [17]. Nootropic agents such as piracetam are commonly prescribed in Europe for the treatment of dementia, including dementia associated with AD, but there are insufficient evidences to verify the efficacy of such drugs [18].

Historically, a number of medicinal herbs have been used to treat neurodegenerative diseases and cognitive disorders in traditional European, Ayurvedic, and Oriental medicines. Medicinal herbs consist primarily of multiple compounds and may influence multiple mechanisms with multi-target functions. This review concerns five phytochemicals, berberine, curcumin, GRg1, puerarin, and silibinin, that have been recently and mostly investigated as alternative treatments for AD and will discuss the advances in our knowledge about these phytochemicals derived from medicinal herbs based on available literature facts collected from books and scientific papers by electronic search (PubMed, ScienceDirect, and Google Scholar) (Fig. 1).

Therapeutic Approaches to Alzheimer’s Disease

Berberine from the cortex of Coptis chinensis

Berberine, an isoquinoline alkaloid, is one of the major components of Cortex Phellodendri and Rhizoma Coptidis (Coptis chinensis, Franch.; Ranunculaceae). Berberine has been used in herbal medicine for liver disease, skin inflammation, diarrhea, and other disorders due to its anti-diarrheal, anti-microbial, and anti-inflammatory effects [8, 19–21]. Specifically, several studies have reported that berberine possesses multiple pharmacological effects that culminate in neuroprotective action against cerebral ischemia, psychological depression, schizophrenia, anxiety, and AD [22, 23]. Asai et al. reported that berberine reduces extracellular Aβ production and BACE activity without changes on release of LDH in H4 neuroglioma (APP751-H4) cells [8]. The production of both Aβ and β-secretase are inhibited by berberine compared with the control in human embryonic kidney 293 (HEK293) cells. Berberine increased the expression level of p-ERK1/2, demonstrating that it may inhibit the production of Aβ via an activation of ERK1/2-induced BACE activity in HEK293 [24].

In another study, the effect of berberine on Aβ-induced neuroinflammation was examined in primary and BV2 microglial cells. Pretreatment with berberine reduces Aβ-induced IL-6 production and MCP-1 release, as well as expression of Cox-2 and inducible i-Nos. Subsequently, NF-κB and the phosphorylation of IkB-α, Akt, p38 kinase, and ERK1/2, but not JNK, stimulated by Aβ, are regulated following treatment with berberine [25]. Moreover, pretreatment with berberine reduced Aβ-stimulated activities of LDH and TNF-α with down-regulation of TNF receptor 1 in SK-N-SH neuroblastoma cells [26].

In APP transgenic mice, berberine treatment improved cognitive impairment as reflected in reductions in errors in the MWM task with respect to both conventional reference memory and memory retention (probe trial). Aβ plaque immunostaining in TgCRND8 mice was associated with reductions in both the number and the area of coronal sections of the cortex and hippocampus following treatment with berberine. Moreover, consistent with the indication that berberine treatment reduces the accumulation of total Aβ peptides in the brain, a significant reduction was found in the degree of microgliosis by Iba-1 burden and astrocytosis by GFAP burden. The mechanisms underlying the benefits of berberine on cognitive function and Aβ neuropathology in TgCRND8 mice were expressed for CTF, APP, and tau phosphorylation. An inhibition of PI3K/Akt/GSK3β activities in the TgCRND8 mouse brain...
influenced CTF and p-APP levels and led to a blockage of Aβ accumulation [27] (Table 1).

**Curcumin from Curcuma longa**

Curcumin, a hydrophobic polyphenol, is isolated from the rhizome of the herb *Curcuma longa* L. (Zingiberaceae). It is one of the active components of turmeric involved in antioxidant, anti-inflammatory, metal chelators, anti-amyloid, anti-tau, and neuroprotective activities [13]. In addition, curcumin has been reported to bind to Aβ and prevent aggregation [28] and protect against cell death, as indicated by increased cell viability and decreased TUNEL-positive cells in rat primary neuron cells infected by adeno-5 virus packaged with iAβ1–42. Curcumin treatment decreased ROS level and protected from intracellular Aβ toxicity [12]. It also inhibited the expression of ROS in acrolein-induced toxicity on SK-N-SH human neuroblastoma cell with increasing

![Chemical structures of phytochemicals from medicinal herbs.](Color figure available online only.)

**Table 1** Summary of findings on berberine as alternative treatment for Alzheimer’s disease.

<table>
<thead>
<tr>
<th>First author, year [ref]</th>
<th>Study design</th>
<th>Treatments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asai et al., 2006 [17]</td>
<td>APP-NL-H4 cells (H4 neuroglioma)</td>
<td>10, 20, 30, 40, 50, 100 µM berberine for 48 h</td>
<td>↔ release of LDH ↓ β-secretase activity</td>
</tr>
<tr>
<td>Zhu et al., 2011 [23]</td>
<td>HEK293 cells (human embryonic kidney 293)</td>
<td>1, 5, 10, 20 µM berberine for 24 h</td>
<td>↔ cell viability ↔ release of LDH ↓ extracellular Aβ40/42 levels ↓ BACE activity ↑ phosphorylation of ERK1/2</td>
</tr>
<tr>
<td>Jia et al., 2012 [24]</td>
<td>Murine primary cells and microglia cells and cultured BV2 cells (murine microglia)</td>
<td>Pretreatment of 1, 2.5, 5 µM berberine for 30 min and 20 µM Aβ25-35 for 24 h</td>
<td>↓ IL-6 production and MCP-1 release ↓ Cox-2 and i-Nos expressions ↓ NF-κB ↓ phosphorylation of IkB-α, Akt, p38 kinase and ERK1/2 ↔ phosphorylation of JNK</td>
</tr>
<tr>
<td>Xu et al., 2013 [25]</td>
<td>SK-N-SH cell (neuroblastoma)</td>
<td>Pretreatment of 10 µM berberine for 2 h and incubation of 5 µM Aβ25-35 for 24 h</td>
<td>↓ LDH activity ↓ level of TNF-α ↓ TNFR1 gene and protein expressions</td>
</tr>
<tr>
<td>Durairajan et al., 2012 [26]</td>
<td>TgCRND8 mice</td>
<td>Orally administered by gavage once daily with a 25 mg/kg and 100 mg/kg dose of berberine for 6 months</td>
<td>↓ MWM task ↓ number and area of Aβ plaque ↓ Iba-1 and GFAP burden ↓ CTF-α and -β expression ↓ levels of p-APP ↑ phosphorylation of Akt at Ser 473 and GSK3β at Ser21 and Ser9</td>
</tr>
</tbody>
</table>

↑ Increase; ↓ decrease; ↔ no difference
LDH release. Lipid peroxidation and oxidative stress by acrolein were protected by curcumin treatment. In addition, the expressions of γ-GCS synthetase and RNS levels, except GSH, were restored by treatment of curcumin. Other oxidative damage marker expressions, such as those of Nrf2, NF-κB, Sirt1, and Akt, were regulated under the presence of curcumin [13].

In other type of human neuroblastoma (SH-SY5Y cells), curcumin regulated under the presence of curcumin [13]. This change was accompanied with decreased GSK3β expression, such as those of Nrf2, NF-κB, Sirt1, and Akt, were regulated under the presence of curcumin [13]. Other oxidative damage marker expressions, such as those of Nrf2, NF-κB, Sirt1, and Akt, were regulated under the presence of curcumin [13].

Furthermore, curcumin has shown beneficial effects through hippocampal-dependent memory improvement. Treatment with curcumin improved the spontaneous alternation behavior as well as the recognition memory task in Aβ-infused rats. Concerning protection of cognitive impairment, a decrease in SYN levels was blocked and the phosphorylation of tau protein in rat hippocampus was decreased under the presence of curcumin. The production of TNF-α and IL-1β and activation of GFAP immunocounter levels were decreased in curcumin-treated hippocampus compared with non-treated samples. Additionally, BDNF concentration and the phosphorylation of Akt and GSK3β revealed an increase after curcumin treatment [31] (Table 2).

Table 2 Summary of findings on curcumin as alternative treatment for Alzheimer’s disease.

<table>
<thead>
<tr>
<th>First author, year [ref]</th>
<th>Study design</th>
<th>Treatments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ye et al., 2012 [10]</td>
<td>Rat primary neurons from new born Sprague-Dawley rat hippocampus</td>
<td>Infection of by adeno-5 virus packaged with Aβ(1-42) and treatment with 30 μM curcumin for 24 h</td>
<td>↑ LDH release ↓ TUNEL+ cells ↓ stained ROS levels</td>
</tr>
<tr>
<td>Doggai et al., 2013 [11]</td>
<td>SK-N-SH cell (neuroblastoma)</td>
<td>Cotreatment with 5, 10, or 20 μM curcumin and acrolein for 24 h and 30 min</td>
<td>↑ LDH release ↑ cell survival ↓ ROS levels ↓ γ-GCS expression ↑ RNS level ↔ GSH ↓ Nrf2 ↓ NF-κB ↓ Sirt1 ↑ phosphorylation of Akt</td>
</tr>
<tr>
<td>Huang et al., 2013 [28]</td>
<td>SH-SYSY cell (human neuroblastoma)</td>
<td>Treatment with cultured with 1, 5, or 10 mM curcumin for 4 h and then continued incubating with 10 mM Aβ(1-42) for 24 h</td>
<td>↓ tau phosphorylation ↑ phosphorylation of GSK3β at Ser9 ↑ phosphorylations of Akt at Thr308 and Ser473 ↓ up-regulation of PTEN</td>
</tr>
<tr>
<td>Xiong et al., 2011 [29]</td>
<td>pAPPswe-transfected SH-SYSY cell</td>
<td>Treatment with curcumin at 0, 1.25, 5, or 20 μM for 24 h, or at 5.0 μM for 0, 12, 24, or 48 h</td>
<td>↓ extracellular Aβ40/42 levels ↓ PS1 mRNA and protein levels ↓ GSK3β mRNA and protein levels</td>
</tr>
<tr>
<td>Hoppe et al., 2013 [30]</td>
<td>Wistar rat</td>
<td>Intracerebroventricular injection of Aβ1-42 and after 2 weeks, administration of 50 mg/kg curcumin intraperitoneally for 10 days</td>
<td>↑ spontaneous alternation in the Y-maze ↑ novel object recognition memory task ↑ SYN levels ↓ tau phosphorylation ↓ TNF-α and IL-1β ↓ GFAP+ immunocounter levels ↓ BDNF ↓ phosphorylations of Akt ↑ phosphorylation of GSK3β</td>
</tr>
</tbody>
</table>

↑ Increase; ↓ decrease; ↔ no difference
In addition, GRg1-treated cortical neurons from C57BL/6 mouse fetuses with Aβ1–42 inhibited the expression of Cyt c in cytosolic fraction, whereas Cyt c levels in mitochondrial fractions were increased. In cortical neurons from embryonic rat fetuses, GRg1 treatment protected Aβ25–35-induced cell death. Bcl-2/Bax ratio was increased with reduced caspase-9 and –3 activities by GRg1 treatment. Release Cyt c from mitochondria was blocked with GRg1 treatment [37]. Similarly, increased LDH release was suppressed against cytotoxicity of Aβ25–35 under the presence of GRg1. GRg1 reduced the numbers of apoptotic cells, as shown in decreased annexin V+/PI fraction. The ratio of Bcl-2/Bax was up-regulated and activation of caspase-3 was down-regulated by GRg1 treatment [38].

In an animal study, Fang et al. demonstrated the neuroprotective effects of GRg1 in transgenic AD mice. ELISA and immunostaining with an Aβ antibody revealed that Aβ plaque loads were lower in the cerebral cortex and hippocampus of GRg1-treated mAPP mice than in vehicle-treated mice. This lower accumulation of Aβ in the cortices of GRg1-treated mice stemmed from the inhibition of γ-secretase activity and did not affect levels of AChE-positive neurites in the entorhinal cortex. Compared with vehicle-treated mAPP mice, GRg1-treated mice were shown to improve their performance in RAWM task [39] (Table 3).

Table 3  Summary of findings on ginsenoside Rg1 as alternative treatment for Alzheimer’s disease.

<table>
<thead>
<tr>
<th>First author, year [ref]</th>
<th>Study design</th>
<th>Treatments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang and Du, 2009 [32]</td>
<td>PC12 cells (rat pheochromocytoma)</td>
<td>Pretreatment with 0.1, 1, 10 µM GRg1 for 1 h and incubation with 50 µM Aβ25–35 for 48 h</td>
<td>↓ activity of β-secretase ↓ cell survival ↓ excessive LDH efflux ↓ excessive generation of NO level ↓ ROS generation ↓ MDA level ↑ rise of [Ca2+]↓ ↑ caspase-3 activity</td>
</tr>
<tr>
<td>Li et al., 2012a [33]</td>
<td>SK-N-SH neuroblastoma cells induced by Aβ-stimulated THP-1 supernatant</td>
<td>Pretreatment with 50, 100 and 150 µM GRg1 for 30 min and then incubation with 125 nM Aβ1–40</td>
<td>↓ LDH leakage ↓ tau-phosphorylation ↓ content of IL-1β release ↑ MAP-2 expression ↑ SYN expression ↑ phosphorylation of p38</td>
</tr>
<tr>
<td>Li et al., 2012b [34]</td>
<td>SK-N-SH neuroblastoma cells induced by Aβ-stimulated THP-1 supernatant</td>
<td>Pretreatment with 50, 100, and 150 µM GRg1 for 30 min and then incubation with 125 nM Aβ1–40 for 2 h</td>
<td>↓ LDH release ↓ levels of IL-1β, IL-8, and TNF-α ↓ TUNEL-positive cells ↓ annexin V-FITC ↑ ratio of Bcl-2/Bax ↑ caspase-3 expression</td>
</tr>
<tr>
<td>Huang et al., 2012 [35]</td>
<td>Cortical neurons from C57BL/6 mouse fetuses</td>
<td>Pretreatment with GRg1 for 24 h, and then incubation with 5 µM Aβ1–42 for 48 h</td>
<td>↑ Cyt c release from mitochondria ↑ TUNEL+ neurons ↑ activity of caspase-3</td>
</tr>
<tr>
<td>Wu et al., 2012 [36]</td>
<td>Cortical neurons from embryonic (E18d) rat fetus</td>
<td>Pretreatment with 1, 10, 20 µM GRg1 for 24 h and incubation with 10 with 10 µM Aβ25–35 for 72 h</td>
<td>↑ cell viability ↑ Bcl-2/Bax ratio ↑ release of Cyt c ↑ caspase-9 ↓ caspase-3</td>
</tr>
<tr>
<td>Gong et al., 2011 [37]</td>
<td>Primary cultured hippocampal neurons from embryonic brains of Wistar rats</td>
<td>Pretreatment with 1 mg/ml Aβ25–35 for 7 days and incubation with GRg1 0.1, 1, 10 µM for 72 h</td>
<td>↑ cell viability ↓ LDH release ↓ annexin V+/PI fraction ↓ Bcl-2/Bax ratio ↓ caspase-3</td>
</tr>
<tr>
<td>Fang et al., 2012 [38]</td>
<td>Tg mAPP (transgenic mice with neuronal overexpression of a mutant human form of amyloid precursor protein)</td>
<td>Four experimental groups: (1) non Tg with vehicle-treated group (2) non Tg with 1 mg/kg GRg1-treated group (3) Tg mAPP with vehicle-treated group (4) Tg mAPP with 1 mg/kg GRg1-treated group</td>
<td>↓ levels of Aβ1–40 and Aβ1–42 ↓ Aβ plaque loads ↓ γ-secretase activity ↔ levels of AChE-positive neuritis ↑ radial arm water maze</td>
</tr>
</tbody>
</table>

† Increase; ↓ decrease; ↔ no difference
Table 4 Summary of findings on puerarin as alternative treatment for Alzheimer’s disease.

<table>
<thead>
<tr>
<th>First author, year [ref]</th>
<th>Study design</th>
<th>Treatments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zou et al., 2013 [41]</td>
<td>Primary cultured hippocampal neurons from Sprague – Dawley rats</td>
<td>Pretreatment with 3, 10, 30, 100 µM puerarin for 2 hours and addition with 20 µM Aβ25-35 for 24 h</td>
<td>↑ cell viability</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ ROS levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ phosphorylation of GSK3β at Ser9</td>
</tr>
<tr>
<td>Lin et al., 2012 [42]</td>
<td>Primary cultured hippocampal neurons from Sprague – Dawley rats</td>
<td>Pretreatment with 3, 10, 30, 100 µM puerarin for 2 hours and addition with 20 µM Aβ25-35 for 24 h</td>
<td>↑ cell viability</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ GSK3β activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ phosphorylation of Akt</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ level of GSH-Px</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ level of CAT activity</td>
</tr>
<tr>
<td>Zhang et al., 2008 [43]</td>
<td>PC12 cells (rat pheochromocytoma)</td>
<td>Preincubation with 0.1, 1, and 10 µM puerarin for 30 min and addition with 50 µM Aβ25-35 for 24 h</td>
<td>↑ cell viability</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ TUNEL-positive cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ annexin V+/PI' fraction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ expression of Bcl-2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ expression of Bax</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ caspase-3</td>
</tr>
<tr>
<td>Zhang et al., 2011 [44]</td>
<td>mitochondrial transgenic neuronal cell used Rho° SH-SY5Y cells lacking mtDNA</td>
<td>Treatment with 0.1, 1, and 10 µM puerarin for 24 hours</td>
<td>↑ cell viability of SAD cybrids</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ annexin V+/PI' fraction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ intracellular ROS generation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ expression of Bcl-2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ expression of Bax</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ phosphorylation of JNK and p38</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ caspase-3 activity</td>
</tr>
<tr>
<td>Li et al., 2010 [45]</td>
<td>Male Sprague–Dawley rats</td>
<td>Intracerebroventricular injection of 10 µg/µL Aβ25-42 and after 3 days, orally administration by gavage with puerarin for 28 days; Six experimental groups: (1) sham-operated group (2) saline-treated Aβ25-42 group (3) donepezil-treated Aβ25-42 group (4) 25 mg/kg puerarin-treated Aβ25-42 group (5) 50 mg/kg puerarin-treated Aβ25-42 group (6) 25 mg/kg puerarin-treated Aβ25-42 group</td>
<td>↓ MWM task</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ number of crossings over a platform position</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ TUNEL-positive cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ phosphorylation of Akt-ser473 and -bad levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↔ unchange on total Akt and Bad levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ caspase-9 protein and mRNA levels</td>
</tr>
</tbody>
</table>

* Increase; ↓ decrease; ↔ no difference

Silibinin from the herb milk thistle (Silybum marianum)
Silibinin is a flavonoid derived from the herb milk thistle (Silybum marianum (L.) Gaertn.; Asteraceae) and is known to have anti-oxidative and anti-inflammatory properties [47]. Various studies have indicated that silibinin confers protection against oxidative stress in hepatocytes by decreasing lipid peroxidation, a sensitive marker of oxidative lipids and scavenging of free radicals [48,49]. Silibinin is protective against Aβ-induced oxidative stress in SH-SY5Y human neuroblastoma cells. The aggregation of Aβ was markedly inhibited following treatment with silibinin in TH/β binding assay and TEM imaging assay. The presence of silibinin with Aβ increased cell viability, whereas its absence decreased it. Additionally, the level of H2O2 in Aβ-treated cells decreased following incubation with silibinin [50]. In animal experiments, silibinin ameliorates Aβ-induced short-term memory impairment as measured by a spontaneous alternation behavior task (Y-maze test) although no significant differences in the number of spontaneous locomotor activities were observed. Recognition memory in novel object recognition tests was improved by silibinin in Aβ-injected mice, while the amounts of time spent exploring objects in training and retention sessions did not differ. To further explore the effects of silibinin on Aβ-induced oxidative stress, levels of MDA and GSH were analyzed. Treatment with silibinin appeared to decrease MDA levels and increase GSH levels in the hippocampus [51]. The cued freezing response and contextual freezing response were attenuated in silibinin-treated animals, indicating an impairment in associative memory. However, silibinin did not change the level of response to electric foot shock (flinching, vocalization, and jumping) in either group. A significant increase in nitrotyrosine, TNF-α, and i-Nos levels in the hippocampus and amygdala were reduced following treatment with silibinin compared with distilled water [52] (Table 5).

Discussion
The aggregation and accumulation of extracellular and intracellular Aβ induce impaired synaptic plasticity and memory [4]. Three proteases, such as α-, β-, and γ-secretases, cleave APP and generate the physiological peptide Aβ along with increased production of CTFs [53–55]. These soluble peptides spontaneously aggregate to form Aβ oligomers and fibrils that are subsequently deposited within the brain to form amyloid plaques [56]. The intracerebroventricular administration of Aβ peptide induces histological and biochemical changes, memory deficits, oxidative...
damage, and inflammatory responses [4, 5]. Based on our review, berberine, GRg1, and silibinin appear to block the formation of Aβ via an inhibition of β-secretase activity. In addition, GRg1 suppressed γ-secretase activity. The PI3K/Akt/GSK3β signaling pathway is associated with various aspects of AD pathology. PI3K regulates the trafficking of intracellular APP-CTFs, whereas GSK modulates APP processing and thereby influences the production of Aβ in neurons. Inhibition of PI3K contributes to tau phosphorylation and impairment in spatial memory. Suppressing GSK3 activity, which is induced by phosphorylation at specific serine residues (Ser 9 and Ser21) by Akt, has been demonstrated to contribute to the accumulation of Aβ in APP mice and the hyperphosphorylation of tau protein [57–62]. Berberine, curcumin, and puerarin regulated the PI3K/Akt/GSK3β signaling pathway. Berberine increased the phosphorylation of Akt and GSK3β, resulting in decreases of APP-CTFs levels. In vitro and in vivo data demonstrated that curcumin exhibits significant increases in the phosphorylation of Akt and GSK3β. Puerarin also upregulated the phosphorylation of GSK3β and Akt. The activation of glial cells and the expression of inflammatory mediators in conjunction with the presence of neurotoxic free radicals lead to neuroinflammation. Activated microglial cells induced by Aβ are able to engulf filament Aβ; thus, the decrease in the Iba-1 burden correlates with a reduced plaque burden [63–65]. Release of proinflammatory cytokines, such as IL-6, IL-1β, and TNF-α, along with chemokines is responsible for the initiation and progression of inflammatory responses [66–68]. Several studies have shown that IL-6 induces the processing of APP and regulates Aβ production [69]. Microglia and macrophages are a major source of TNF-α although TNF-α is also expressed to a lesser extent by GFAP-positive astrocytes, and IL-1β is expressed by neurons and astrocytes in response to AD-like pathology [66, 67]. High level of MCP-1 promotes the migration and recruitment of inflammatory cells [70, 71]. Furthermore, Aβ-induced MCP-1 mRNA expression is associated with the activation of the PI3K/Akt signaling pathway [72]. Additionally, NF-κB, and its key inhibitor, IκB-α, primary regulator of inflammatory processes in almost all cell types including neurons, are expressed in microglial cells that express i-Nos and Cox-2 [73, 74]. Previous studies have shown that the MAPK signaling pathways play an important role in the regulation of chemokine and pro-inflammatory cytokine production in microglia [75, 76]. Berberine, curcumin, and GRg1 suppressed the activation of microglial cells and neuroinflammation by blocking the production of proinflammatory cytokines. Berberine, GRg1, and puerarin inhibited NF-κB and MAPK signaling pathways. In particular, berberine decreased the Iba-1 burden, indicating a reduction in the degree of microgliosis. In addition, treatment with berberine reduced IL-6 production and MCP-1 release in microglial cells. and suppressed NF-κB translocation into the nucleus as well as the phosphorylation of IκB-α, ERK1/2, and p38. Curcumin treatment showed a significant decrease in activated microglia along with reductions in IL-1β and TNF-α. In case of GRg1, the content of IL-1β, IL-8, and TNF-α were reduced with the phosphorylation of p38 and puerarin attenuated the phosphorylation of JNK and p38, resulting in the protection against neuronal cell death.

Concerning neuron cell survival, the loss of neuron-related apoptosis is regulated by several intracellular signaling events [77]. During early apoptosis stages, the Bcl-2 protein family which includes anti-apoptotic molecules such as Bcl-2 and Bcl-xL, and pro-apoptotic molecules such as Bax, Bak, Bid, and Bad, is related to the formation of channels in mitochondrial membranes. The Bcl-2/Bax ratio, in particular, is crucial for initiating apoptosis, and its translocation to the mitochondrial membrane may lead to the loss of mitochondrial membrane potential and increased mitochondrial permeability [78] which results in the release of Cyt c from mitochondria and the subsequent activation of procaspase-3 to caspase-3, eventually leading to apoptosis [79]. GRg1 and

<table>
<thead>
<tr>
<th>First author, year [ref]</th>
<th>Study design</th>
<th>Treatments</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yin et al., 2010 [49]</td>
<td>SH-SYSY cells (human neuroblastoma)</td>
<td>Pretreatment of 0, 2.5, 5, 10, 20, 50 µM silibinin and addition with 100 µM Aβ1–42 for 24 h</td>
<td>↓ ThT binding assay ↓ Aβ1–42 aggregation ↓ cytotoxicity of Aβ1–42 ↓ level of H2O2</td>
</tr>
<tr>
<td>Lu et al., 2009a [51]</td>
<td>Male ICR mice</td>
<td>Intracerebroventricular injection of 3 nmol/mouse Aβ25–35, and after 4 days, orally administration by gavage with silibinin for 11 days; Six experimental groups: (1) vehicle-treated group (2) vehicle-treated Aβ25–35 group (3) 2 mg/kg silibinin-treated Aβ25–35 group (4) 20 mg/kg silibinin-treated Aβ25–35 group (5) 200 mg/kg silibinin-treated Aβ25–35 group (6) 200 mg/kg silibinin-treated group</td>
<td>↔ no significant differences in the time course and total of locomotor activity ↑ impairment of spontaneous alternation behaviour ↑ level of exploration preference in the retention session ↓ level of MDA ↑ level of GSH</td>
</tr>
<tr>
<td>Lu et al., 2009b [52]</td>
<td>Male ICR mice</td>
<td>Intracerebroventricular injection of 3 nmol/mouse Aβ25–35, and after 4 days, orally administration by gavage with silibinin for 8 days; Eight experimental groups: (1) vehicle-treated group (2) vehicle-treated Aβ25–35 group (3) 2 mg/kg silibinin-treated Aβ25–35 group (4) 20 mg/kg silibinin-treated Aβ25–35 group (5) 200 mg/kg silibinin-treated Aβ25–35 group (6) 2 mg/kg silibinin-treated group (7) 20 mg/kg silibinin-treated group (8) 200 mg/kg silibinin-treated group</td>
<td>↑ cued and contextual freezing responses ↔ no differences on the levels of electric current required to elicit flinching, vocalization, and jumping ↑ nitrotyrosine levels in the hippocampus and amygdala ↓ i-Nos and TNF-α mRNA expression</td>
</tr>
</tbody>
</table>

† Increase; ↓ decrease; ↔ no difference
puerarin attenuated apoptosis by regulating anti-apoptotic and pro-apoptotic molecules. GRG1 regulated the ratio of Bcl-2/Bax, resulting in the release of Cyt c from mitochondria and the reduction of caspase-9 and caspase-3 activities. Puerarin protected cell death via up-regulating the ratio of Bcl-2/Bax and down-regulating the caspase-9 and –3 activities which were induced by the phosphorylation of Bad.

Furthermore, it is well established that oxidative stress is involved in apoptosis in that excessive production of ROS can lead to neuronal apoptosis in AD [11, 80]. GSH and MDA are important intracellular anti-oxidants necessary for the formation of peroxynitrite and responsible for removing oxygen-free radicals [51, 81]. In addition, the activations of NF-κB, Sirt1, and Nrf2 pathways are related to protection of cells against oxidant damage as stress sensor molecules [82]. Curcumin, GRG1, puerarin, and sili-binin exhibited protection against oxidative stress. Specifically, curcumin regulated g-gcs expression and RNS level. And treatment with GRG1 inhibited the excessive generation of NO and MDA levels as well as ROS generation. Puerarin also decreased intracellular ROS generation while increasing GSH-Px and CAT activities in various neuronal cells. Sili-binin decreased the levels of MDA, whereas GSH was increased in in vivo study.

Apart from the pathology, memory enhancement is one of major issues of AD. Loss of neuroblasts and markers, characteristic of striatal medium spiny neurons, belong to the process of neuronal cell death [83]. In terms of neurotrophic factors, BDNF promotes the survival of new hippocampal neurons [84]. Synaptic proteins take part in the development of nerve synapses and adjust their plasticity. SYN, one of the synaptic proteins, is a marker of synaptic distribution and synaptic density [85]. GRG1 increased SYN expression, and curcumin contributed to the formation of new neurons by regulating the synaptic proteins SYN and BDNF.

To date, evidence from recent studies suggests that commonly used medicinal herbs and their phytochemicals could potentially be used to treat AD. Although these studies focus on the efficacy of inhibiting AD development, and research on humans is limited, numerous findings demonstrate the possibilities of the use of medicinal herbs for the treatment of AD. The approach to investigate the potential treatment of AD may support drug development from herbal medicine.

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2012–0005755).

Conflict of Interest

The authors state no conflict of interest.

References

18. Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001; CD001011
iting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways. Pharmaco 2012; 64: 1510–1521


34 Li W, Chu Y, Zhang L, Yin L, Li L. Ginsenoside Rg1 attenuates tau hyperphosphorylation in SK-N-SH induced by Abeta-stimulated THP-1 supernatant and the involvement of p38 pathway activation. Life Sci 2012; 91: 809–815


38 Gong L, Li SL, Chang LG. Ginsenoside Rg1 protects primary cultured rat hippocampal neurons from cell apoptosis induced by beta-amyloid protein. Pharm Biol 2011; 49: 501–507


72 Ito S, Sawada M, Haneda M, Ishida Y, Isobe K. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci Res 2006; 56: 294–299


85 Ginzel D, Shoshan-Barmatz V. The synaptic vesicle protein synaptoophysin: purification and characterization of its channel activity. Biophys J 2002; 83: 3223–3229